-+ 0.00%
-+ 0.00%
-+ 0.00%

Guggenheim Maintains Buy on NewAmsterdam Pharma Co, Raises Price Target to $45

Benzinga·02/19/2026 14:32:22
Listen to the news
Guggenheim analyst Debjit Chattopadhyay maintains NewAmsterdam Pharma Co (NASDAQ:NAMS) with a Buy and raises the price target from $41 to $45.